Oncology and Hematology

Episodes 113-128 of 128

Interprofessional Coordination of Adverse Event Management
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
CME/CE
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
1.00 credit
- Amir T. Fathi, MD
- Courtney DiNardo, MD
- Brian A. Jonas, MD, PhD
1.00 credit
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
CME/CE
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
1.00 credit
- Matthew S. Davids, MD, MMSc
1.00 credit
Late-Stage Bispecifics and ADCs in DLBCL
Late-Stage Bispecifics and ADCs in DLBCL
MinuteCE®
Late-Stage Bispecifics and ADCs in DLBCL
1.00 program credit
- Sarah Rutherford, MD
- John P. Leonard, MD
1.00 program credit
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
MinuteCE®
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
1.00 program credit
- Alex Herrera, MD
- Alison J. Moskowitz, MD
1.00 program credit
Bispecific Antibodies in FL
Bispecific Antibodies in FL
MinuteCE®
Bispecific Antibodies in FL
1.00 program credit
- Kami Maddocks, MD
- Matthew J. Matasar, MD
1.00 program credit
Individualizing Frontline Treatment
Individualizing Frontline Treatment
MinuteCE®
Individualizing Frontline Treatment
1.00 program credit
- Alex Herrera, MD
- Alison J. Moskowitz, MD
1.00 program credit
MinuteCE®
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
1.00 credit 9 episodes
- John P. Leonard, MD
- Matthew J. Matasar, MD
- Alex Herrera, MD
- Kami Maddocks, MD
- Alison J. Moskowitz, MD
- Sarah Rutherford, MD
1.00 credit 9 episodes
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
MinuteCE®
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
1.00 program credit
- Kami Maddocks, MD
- Matthew J. Matasar, MD
1.00 program credit
Antibody-Drug Conjugates in FL
Antibody-Drug Conjugates in FL
MinuteCE®
Antibody-Drug Conjugates in FL
1.00 program credit
- Matthew J. Matasar, MD
- Kami Maddocks, MD
1.00 program credit
Patient Selection for ADCs in First-Line DLBCL
Patient Selection for ADCs in First-Line DLBCL
MinuteCE®
Patient Selection for ADCs in First-Line DLBCL
1.00 program credit
- John P. Leonard, MD
- Sarah Rutherford, MD
1.00 program credit
Application of Data from the ECHELON-1 Trial
Application of Data from the ECHELON-1 Trial
MinuteCE®
Application of Data from the ECHELON-1 Trial
1.00 program credit
- Alison J. Moskowitz, MD
- Alex Herrera, MD
1.00 program credit
NCCN Guideline Updates in DLBCL
NCCN Guideline Updates in DLBCL
MinuteCE®
NCCN Guideline Updates in DLBCL
1.00 program credit
- John P. Leonard, MD
- Sarah Rutherford, MD
1.00 program credit